Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUMO1 pseudogene 2 (SUMO1P2) is a genomic DNA sequence derived from the SUMO1 gene but lacks the capacity to encode a functional protein. It is categorized as a pseudogene, meaning it is an inactive copy and does not participate in cellular processes attributed to SUMO1 or other SUMO paralogues. Pseudogenes like SUMO1P2 do not have well-defined biological activities but sometimes are studied for potential regulatory effects on their parent genes or as indicators in genomics research[4][5][6]. Note: - The active gene/protein "Small ubiquitin-like modifier 1 (SUMO1)" is involved in post-translational modification (sumoylation), impacting gene expression, nuclear transport, transcriptional regulation, cell cycle, and apoptosis[1][3][5][6]. - SUMO1P2, as a pseudogene, does not share these functional roles and is not itself a therapeutic target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUMO1 pseudogene 2 (SUMO1P2).